RSS Feeds
The Current Status of Diphenylhydantoin* in Heart Disease
- EDWARD N. MERCER, B.A.SC., M.D., F.R.C.P.(C); and
- JOHN A. OSBORNE, B.SC., M.D.
- Requests for reprints should be addressed to John A. Osborne, M.D., Director of Cardiology, Vancouver General Hospital, Vancouver 9, British Columbia, Canada.
Excerpt
Diphenylhydantoin sodium (Dilantin®) is being widely investigated for the treatment of cardiac arrhythmias. The drug appears to offer some advantages, particularly with regard to safety, over other forms of drug therapy. Nonetheless, its use carries certain hazards, some of which may not be widely appreciated. The range of therapeutic usefulness of the drug in heart disease is becoming established, and its mode of action, although not yet fully elucidated, is undergoing intensive investigation. The purpose of this paper is to present data from 6 years' clinical experience with diphenylhydantoin (DPH) in the treatment of cardiac arrhythmias, to review the reported
This 100-word excerpt has been provided in the absence of an abstract.
Article and Author Information
-
From Vancouver General Hospital and The University of British Columbia, Vancouver, British Columbia, Canada.
-
Dr. Mercer was supported in this study by a medical research fellowship from the Canadian Heart Foundation, Toronto, Ontario.
-
↵* Diphenylhydantoin (Dilantin®) is approved by the U. S. Food and Drug Administration for use only as an anticonvulsant; at present in the United States the use of this drug in the treatment of cardiac arrhythmias is investigational only.
-
- Received June 26, 1967.
- Accepted August 7, 1967.
Related Clinical Content
